In early November a bill was put in front of the British
parliament, for second reading, proposing that new licences should
About the Life Sciences Blog
Industry insights from the IHS Markit Life Sciences team covering market access, pricing and reimbursement, emerging markets, generics strategies, therapeutic development pathways, forecasting and market sizing, and general competitive intelligence.
IHS Markit Blog Home »